journal article·2018-07-09

Degradation, Intra-Articular Biocompatibility, Drug Release, and Bioactivity of Tacrolimus-Loaded Poly(d-l-lactide-PEG)-b-poly(l-lactide) Multiblock Copolymer-Based Monospheres

Maria J. Sandker, Luisa F. Duque, Everaldo M. Redout, Evelien C. Klijnstra, Rob Steendam, Nicole Kops, Jan H. Waarsing, Rene van Weeren, Wim E. Hennink, Harrie Weinans

Publisher page

Abstract

-poly(l-lactide) multiblock copolymers were tunable by changing polymer composition, particularly hydrophobic-hydrophilic block ratio. The monospheres were 30 μm and released the drug, depending on the formulation, in 7 to >42 days. The formulation exhibiting sustained release for 1 month was selected for further in vivo evaluation. Rat knees were injected with three different doses of tacrolimus (10 wt %) loaded monospheres (2.5, 5.0, and 10 mg), contralateral control knees with saline. Micro-CT and histology showed no negative changes on cartilage, indicating good biocompatibility. Minor osteophyte formation was seen in a dose dependent fashion, suggesting local drug release and therapeutic action thereof. To investigate in vivo drug release, tacrolimus monospheres were injected into horse joints, after which multiple blood and synovial fluid samples were taken. Sustained intra-articular release was seen during the entire four-week follow-up, with negligible systemic drug concentrations (<1 ng/mL), confirming the feasibility of local intra-articular drug delivery without provoking systemic effects. Intra-articular injection of unloaded monospheres led to a transient inflammatory reaction, measured by total synovial leucocyte count (72 h). This reaction was significantly lower in joints injected with tacrolimus loaded monospheres, showing not only the successful local tacrolimus delivery but also local anti-inflammatory action. This local anti-inflammatory potential without systemic side-effects can be beneficial in the treatment of inflammatory joint diseases, among which is osteoarthritis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Total Knee Arthroplasty Outcomes · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, Erasmus Medical Centre, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands

Department of Orthopaedics, UMC Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

InnoCore Pharmaceuticals, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands

Department of Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands

Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3512 JE Utrecht, The Netherlands

Department of Orthopaedics and Department of Rheumatology, UMC Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

Department of Biomechanical Engineering, TUDelft, Mekelweg 2, 2628 CD Delft, The Netherlands

Funding

Ministerie van Economische Zaken · Reumafonds · BioMedical Materials institute

References (78)

Show source-provided references
1. 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F ↗
2. 10.1097/01.blo.0000144484.69656.e410.1097/01.blo.0000144484.69656.e4 ↗
3. 10.1016/j.joca.2014.01.00310.1016/j.joca.2014.01.003 ↗
4. 10.1177/10600280940280041410.1177/106002809402800414 ↗
5. Kelly P. A. · Am. J. Health Syst. Pharm. · 1995 · 52 · 152110.1093/ajhp/52.14.1521 ↗
6. 10.3109/0300974090350164210.3109/03009740903501642 ↗
7. 10.1136/ard.54.1.3310.1136/ard.54.1.33 ↗
8. Fernandes J. C. · Biorheology · 2002 · 39 · 237
9. 10.1097/BOR.0b013e328349c2b110.1097/BOR.0b013e328349c2b1 ↗
10. 10.1038/nrrheum.2010.15910.1038/nrrheum.2010.159 ↗
11. 10.1007/s11914-017-0411-y10.1007/s11914-017-0411-y ↗
12. 10.1038/sj.bjp.070347210.1038/sj.bjp.0703472 ↗
13. 10.1002/art.2273110.1002/art.22731 ↗
14. Fuseler J. W. · J. Rheumatol · 2000 · 27 · 190
15. 10.1089/ten.tea.2009.008210.1089/ten.tea.2009.0082 ↗
16. 10.1002/art.3436910.1002/art.34369 ↗
17. 10.1007/s00011-003-1210-810.1007/s00011-003-1210-8 ↗
18. 10.1016/j.intimp.2004.10.01210.1016/j.intimp.2004.10.012 ↗
19. 10.1016/S0014-2999(02)01269-410.1016/S0014-2999(02)01269-4 ↗
20. 10.2165/00003088-200443100-0000110.2165/00003088-200443100-00001 ↗
21. 10.1097/00007691-199912000-0000110.1097/00007691-199912000-00001 ↗
22. 10.1097/00007890-199901270-0002610.1097/00007890-199901270-00026 ↗
23. 10.1023/A:101899331277310.1023/A:1018993312773 ↗
24. 10.1016/j.ejps.2005.12.00610.1016/j.ejps.2005.12.006 ↗
25. 10.1002/14651858.CD00532810.1002/14651858.CD005328 ↗
26. 10.2165/00003088-200443100-0000110.2165/00003088-200443100-00001 ↗
27. 10.1007/s10067-008-1079-610.1007/s10067-008-1079-6 ↗
28. 10.1007/s10067-003-0757-710.1007/s10067-003-0757-7 ↗
29. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000, 43 (9), 1905–1915.10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P ↗
30. 10.1016/j.addr.2006.01.01810.1016/j.addr.2006.01.018 ↗
31. 10.1016/j.tvjl.2010.09.01910.1016/j.tvjl.2010.09.019 ↗
32. 10.1002/jps.2134610.1002/jps.21346 ↗
33. 10.1517/17425247.2014.86732510.1517/17425247.2014.867325 ↗
34. 10.1038/nrrheum.2016.21010.1038/nrrheum.2016.210 ↗
35. 10.1016/j.actbio.2016.11.00310.1016/j.actbio.2016.11.003 ↗
36. 10.1016/j.ijpharm.2008.04.04210.1016/j.ijpharm.2008.04.042 ↗
37. 10.1023/A:101444710271010.1023/A:1014447102710 ↗
38. 10.7164/antibiotics.40.124910.7164/antibiotics.40.1249 ↗
39. 10.1016/0731-7085(95)01605-810.1016/0731-7085(95)01605-8 ↗
40. 10.1021/mp200608y10.1021/mp200608y ↗
41. 10.1002/jor.2144410.1002/jor.21444 ↗
42. 10.1016/j.joca.2008.01.01210.1016/j.joca.2008.01.012 ↗
43. 10.1073/pnas.060640610310.1073/pnas.0606406103 ↗
44. 10.1016/j.joca.2016.01.13710.1016/j.joca.2016.01.137 ↗
45. 10.1007/s00011-003-1210-810.1007/s00011-003-1210-8 ↗
46. 10.1186/ar446110.1186/ar4461 ↗
47. 10.1016/j.joca.2008.05.01210.1016/j.joca.2008.05.012 ↗
48. Ross M. W. · 2003 · 66
49. 10.1053/jvet.2001.2843010.1053/jvet.2001.28430 ↗
50. 10.1186/ar342710.1186/ar3427 ↗
51. 10.1186/ar264010.1186/ar2640 ↗
52. 10.1021/bm400804w10.1021/bm400804w ↗
53. 10.1016/j.ejpb.2014.02.01210.1016/j.ejpb.2014.02.012 ↗
54. 10.1016/j.jmbbm.2014.03.00210.1016/j.jmbbm.2014.03.002 ↗
55. 10.1208/s12248-009-9156-610.1208/s12248-009-9156-6 ↗
56. 10.1016/j.jconrel.2004.01.01110.1016/j.jconrel.2004.01.011 ↗
57. 10.1016/j.ijpharm.2011.01.02710.1016/j.ijpharm.2011.01.027 ↗
58. 10.1517/17425247.2012.70984410.1517/17425247.2012.709844 ↗
59. 10.2217/nnm.12.21010.2217/nnm.12.210 ↗
60. 10.1016/j.jconrel.2008.04.00410.1016/j.jconrel.2008.04.004 ↗
61. 10.1016/j.jconrel.2008.01.00410.1016/j.jconrel.2008.01.004 ↗
62. 10.1016/j.biomaterials.2013.07.04610.1016/j.biomaterials.2013.07.046 ↗
63. 10.1016/j.biopha.2013.04.00110.1016/j.biopha.2013.04.001 ↗
64. 10.1016/j.jconrel.2008.08.02110.1016/j.jconrel.2008.08.021 ↗
65. 10.3109/03639045.2011.56577410.3109/03639045.2011.565774 ↗
66. 10.1007/BF0255589810.1007/BF02555898 ↗
67. 10.1186/s13075-015-0735-x10.1186/s13075-015-0735-x ↗
68. 10.1016/j.joca.2014.02.00310.1016/j.joca.2014.02.003 ↗
69. 10.1007/BF0033449010.1007/BF00334490 ↗
70. 10.1073/pnas.050848010210.1073/pnas.0508480102 ↗
71. 10.1016/j.devcel.2006.04.00610.1016/j.devcel.2006.04.006 ↗
72. 10.1007/s00296-012-2370-z10.1007/s00296-012-2370-z ↗
73. 10.1186/ar446110.1186/ar4461 ↗
74. Goldring M. B. · Biology of the Normal Joint, in Kelley and Firestein’s Textbook of Rheumatology · 2013 · 1
75. 10.1136/rmdopen-2017-00052710.1136/rmdopen-2017-000527 ↗
76. 10.1007/s11926-013-0375-610.1007/s11926-013-0375-6 ↗
77. 10.1016/j.biomaterials.2015.02.10910.1016/j.biomaterials.2015.02.109 ↗
78. 10.1186/ar209910.1186/ar2099 ↗